vTv Therapeutics Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing small-molecule drug candidates. The company generated no product revenue in FY2025, recording a net loss attributable to vTv Therapeutics Inc. of $26.97 million against total operating expenses of $32.81 million (year ended December 31, 2025). Its lead drug candidate is cadisegliatin (TTP399), an oral compound in clinical development. The FDA lifted a clinical hold on the cadisegliatin program in March 2025, allowing clinical development to resume. vTv finances operations through equity offerings, debt financings, and licensing or collaboration arrangements, as no product has received commercial approval. Research and development expenses were $17.86 million in FY2025, up from $11.55 million in FY2024. The company carries $10.0 million in clinical trial liability insurance. Investors include G42 Investments AI Holdings and entities affiliated with CinRx Pharma.

Revenue model

No product revenue was recorded in FY2025. FY2024 revenue of $1.017 million was the sole recent revenue period disclosed in the filing. The company funds operations through equity issuances, including an at-the-market offering program, securities purchase agreements, and potential future licensing or collaboration arrangements.

Products and services

Cadisegliatin (TTP399) is the lead drug candidate, an oral small-molecule compound in clinical development. A food effect study completed in December 2025 showed higher drug exposure when taken with food, confirming the recommended fed dosing regimen. The company completed an open-label Phase 1 absorption, metabolism, and excretion study in August 2023.

Customers and end markets

No commercial customers. The end market is pharmaceutical development targeting conditions addressable by cadisegliatin, with the FDA as the primary regulatory gatekeeper for any future commercialization in the United States.

Value-chain role

Pre-commercial drug developer. The company conducts clinical trials, manages regulatory interactions with the FDA, and holds patents on its drug candidates. It does not manufacture or sell commercial products as of December 31, 2025.

Geographic exposure

Primary regulatory and operational focus is the United States, based on FDA interactions and USPTO patent activity described in the filing. No commercial geographic revenue mix is disclosed.

Source: SEC 10-K, filed 2026-03-10

Industry: Pharmaceutical Preparations Peers: BIORA THERAPEUTICS, INC. Elutia Inc Candel Therapeutics Inc CytomX Therapeutics Inc Decibel Therapeutics, Inc. Galectin Therapeutics Inc Immunic Inc Insight Molecular Diagnostics Inc